CDD-2807

• UNSPSC Description:

  CDD-2807 is an inhibitor for serine/threonine kinase 33 (STK33) with IC50 of 9.2 nM. CDD-2807 exhibits no significant toxicity in mice and can cross the blood-testis barrier without accumulating in the brain. CDD-2807 induces a reversible contraceptive effect and has potential for the development of the male contraceptive[1].

• Target Antigen:

  CDK; RET; STK33

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Protein Tyrosine Kinase/RTK

• Field of Research:

  Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/cdd-2807.html

• Smiles:

  O=C(C1=CC2=C(NN=C2C#CC3=CC=CC=C3C4=CC=CC=C4)C=C1)N5CC6(CNCCC6)C5

• Molecular Weight:

  446.54

• References & Citations:

  [1]Ku AF, et al., Reversible male contraception by targeted inhibition of serine/threonine kinase 33. Science. 2024 May 24;384(6698):885-890.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported